186 related articles for article (PubMed ID: 25983023)
1. Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients.
McCune JS; Mager DE; Bemer MJ; Sandmaier BM; Storer BE; Heimfeld S
Cancer Chemother Pharmacol; 2015 Jul; 76(1):85-96. PubMed ID: 25983023
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients.
McCune JS; Woodahl EL; Furlong T; Storer B; Wang J; Heimfeld S; Deeg HJ; O'Donnell PV
Cancer Chemother Pharmacol; 2012 Jan; 69(1):263-72. PubMed ID: 21909959
[TBL] [Abstract][Full Text] [Related]
4. A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients.
Woodahl EL; Wang J; Heimfeld S; Sandmaier BM; O'Donnell PV; Phillips B; Risler L; Blough DK; McCune JS
Cancer Chemother Pharmacol; 2009 Feb; 63(3):391-401. PubMed ID: 18398611
[TBL] [Abstract][Full Text] [Related]
5. A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients.
Bemer MJ; Sorror M; Sandmaier BM; O'Donnell PV; McCune JS
Cancer Chemother Pharmacol; 2013 Sep; 72(3):607-18. PubMed ID: 23907443
[TBL] [Abstract][Full Text] [Related]
6. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
7. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
[TBL] [Abstract][Full Text] [Related]
8. Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Following Flu-TBI versus TLI-ATG Conditioning.
Hannon M; Beguin Y; Ehx G; Servais S; Seidel L; Graux C; Maertens J; Kerre T; Daulne C; de Bock M; Fillet M; Ory A; Willems E; Gothot A; Humblet-Baron S; Baron F
Clin Cancer Res; 2015 Jul; 21(14):3131-9. PubMed ID: 25779951
[TBL] [Abstract][Full Text] [Related]
9. Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society.
Baron F; Zachée P; Maertens J; Kerre T; Ory A; Seidel L; Graux C; Lewalle P; Van Gelder M; Theunissen K; Willems E; Emonds MP; De Becker A; Beguin Y
J Hematol Oncol; 2015 Feb; 8():4. PubMed ID: 25652604
[TBL] [Abstract][Full Text] [Related]
10. Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning.
Sanghavi K; Wiseman A; Kirstein MN; Cao Q; Brundage R; Jensen K; Rogosheske J; Kurtzweil A; Long-Boyle J; Wagner J; Warlick ED; Brunstein CG; Weisdorf DJ; Jacobson PA
Transl Res; 2016 Sep; 175():103-115.e4. PubMed ID: 27094990
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients.
Ivaturi V; Dvorak CC; Chan D; Liu T; Cowan MJ; Wahlstrom J; Stricherz M; Jennissen C; Orchard PJ; Tolar J; Pai SY; Huang L; Aweeka F; Long-Boyle J
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1701-1713. PubMed ID: 28684371
[TBL] [Abstract][Full Text] [Related]
12. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
[TBL] [Abstract][Full Text] [Related]
13. Higher Fludarabine and Cyclophosphamide Exposures Lead to Worse Outcomes in Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Adult Hematologic Malignancy.
Takahashi T; Scheibner A; Cao Q; Pearson R; Sanghavi K; Weisdorf DJ; Brunstein CG; Rogosheske J; Bachanova V; Warlick ED; Wiseman A; Jacobson PA
Transplant Cell Ther; 2021 Sep; 27(9):773.e1-773.e8. PubMed ID: 34044184
[TBL] [Abstract][Full Text] [Related]
14. F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan.
Bonin M; Pursche S; Bergeman T; Leopold T; Illmer T; Ehninger G; Schleyer E; Bornhauser M
Bone Marrow Transplant; 2007 Feb; 39(4):201-6. PubMed ID: 17211431
[TBL] [Abstract][Full Text] [Related]
15. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
[TBL] [Abstract][Full Text] [Related]
16. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
[TBL] [Abstract][Full Text] [Related]
17. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation.
Baron F; Maris MB; Storer BE; Sandmaier BM; Panse JP; Chauncey TR; Sorror M; Little MT; Maloney DG; Storb R; Heimfeld S
Leukemia; 2005 May; 19(5):822-8. PubMed ID: 15772701
[TBL] [Abstract][Full Text] [Related]
18. High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation.
Long-Boyle JR; Green KG; Brunstein CG; Cao Q; Rogosheske J; Weisdorf DJ; Miller JS; Wagner JE; McGlave PB; Jacobson PA
Bone Marrow Transplant; 2011 Jan; 46(1):20-6. PubMed ID: 20383215
[TBL] [Abstract][Full Text] [Related]
19. A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic cell transplant patients.
Salinger DH; Blough DK; Vicini P; Anasetti C; O'Donnell PV; Sandmaier BM; McCune JS
Clin Cancer Res; 2009 Aug; 15(16):5280-7. PubMed ID: 19671874
[TBL] [Abstract][Full Text] [Related]
20. Cellular and clinical pharmacology of fludarabine.
Gandhi V; Plunkett W
Clin Pharmacokinet; 2002; 41(2):93-103. PubMed ID: 11888330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
